IGF-1 LR3 dosage: reported doses and schedule
An unapproved growth signal with no human trials found.
Also called: Long R3 IGF-I, Long Arg3 IGF-1, LR3-IGF-1, Long-[Arg3]IGF-I.
IGF-1 and analogues · Modified IGF-1 receptor agonist · Evidence: Animal studies only.
Typical reported dose: 20–40 mcg once a day
- Reported 20–40 mcg daily: 20–40 mcg once daily once daily, under the skin. Reported by users, common report. Studied in: Adults discussing physique use. (source)
- Reported 50 mcg with breaks: 50 mcg per injection; the commenter did not state frequency not stated in this comment, under the skin. Reported by users, occasional report. Studied in: An adult forum commenter reporting SC use. (source)
- Reported 100 mcg into muscle: 100 mcg once daily once daily, into muscle. Reported by users, rare report. Studied in: An adult commenter reporting actual use. (source)
- Forum guide with longer cycles: 30–80 mcg daily, or a separate 50–120 mcg daily range once daily, under the skin. Reported by users, occasional report. Studied in: A community guide, not a clinical study. (source)
- One reported 20→40→60 mcg cycle: 20 mcg in week 1; 40 mcg in middle weeks; 60 mcg in the final week of a 5–6-week cycle before workouts; dosing frequency not stated, under the skin. Reported by users, rare report. Studied in: One 23-year-old man reporting SC pre-workout use. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to IGF-1 LR3
- Mecasermin: Prescription IGF-1 approved for rare childhood growth failure; low blood sugar is a major risk.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Somatropin: Prescription human growth hormone, with no proven anti-aging benefit.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- INCRELEX (mecasermin) injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Increlex, European Medicines Agency
- Increlex, INN-mecasermin, European Medicines Agency
- Know When to Go to the ER, American College of Emergency Physicians · American College of Emergency Physicians
- Mecasermin (Increlex▼): risk of benign and malignant neoplasia, MHRA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.